TransGenic Group (2342.T) Akcie Kurz

Trans Genic Inc. engages in the development, distribution, and licensing of genetically engineered animals and antibodies. The company is headquartered in Fukuoka, Fukuoka-Ken and currently employs 236 full-time employees. The company went IPO on 2002-12-10. The firm has three business segments. The Contract Research Organization (CRO) segment is engaged in the provision of contract clinical tests for pharmaceuticals and foods, pharmacodynamic pharmacology tests, safety pharmacology tests, pharmacokinetic tests, and non-clinical tests such as safety tests for pesticides and food, the contract production of genetically modified mice and antibody, the sale of model mice, as well as the development of new biomarkers. The Diagnostic Analysis segment is engaged in the provision of pathological diagnosis services, gene analysis contract services, and drug discovery support services for individualized medicine. The TGBS segment is engaged in the provision of advice and support services for business succession and revitalization in various fields, as well as the electronic commerce (EC) business such as the retail and wholesale of electrical products.